Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

SIRAGUSA, Sergio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.181
EU - Europa 5.966
AS - Asia 1.322
SA - Sud America 17
AF - Africa 12
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 9
Totale 22.517
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.123
IT - Italia 2.096
CN - Cina 991
UA - Ucraina 890
DE - Germania 740
FI - Finlandia 716
IE - Irlanda 348
GB - Regno Unito 309
SE - Svezia 229
RU - Federazione Russa 174
FR - Francia 148
RO - Romania 76
BE - Belgio 70
KR - Corea 69
IN - India 64
CA - Canada 53
TR - Turchia 51
PL - Polonia 36
CH - Svizzera 32
IR - Iran 31
HK - Hong Kong 26
NL - Olanda 26
GR - Grecia 18
AT - Austria 15
ES - Italia 15
BR - Brasile 13
PK - Pakistan 13
ID - Indonesia 12
SG - Singapore 11
UZ - Uzbekistan 11
CZ - Repubblica Ceca 10
EU - Europa 8
LB - Libano 7
NZ - Nuova Zelanda 5
AU - Australia 4
IQ - Iraq 4
BD - Bangladesh 3
BG - Bulgaria 3
CO - Colombia 3
JP - Giappone 3
MY - Malesia 3
PH - Filippine 3
SA - Arabia Saudita 3
TW - Taiwan 3
VN - Vietnam 3
ZA - Sudafrica 3
A2 - ???statistics.table.value.countryCode.A2??? 2
EE - Estonia 2
ET - Etiopia 2
HR - Croazia 2
IL - Israele 2
KZ - Kazakistan 2
MA - Marocco 2
MM - Myanmar 2
MX - Messico 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AO - Angola 1
CI - Costa d'Avorio 1
CL - Cile 1
CR - Costa Rica 1
DK - Danimarca 1
DZ - Algeria 1
EG - Egitto 1
HU - Ungheria 1
KH - Cambogia 1
KW - Kuwait 1
LU - Lussemburgo 1
LV - Lettonia 1
LY - Libia 1
MD - Moldavia 1
NO - Norvegia 1
PA - Panama 1
PR - Porto Rico 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
Totale 22.517
Salva come PNG Salva come JPEG
Città #
Fairfield 2.383
Ashburn 1.539
Chandler 1.248
Woodbridge 1.246
Houston 1.189
Wilmington 993
Seattle 894
Cambridge 755
Ann Arbor 633
Jacksonville 458
Medford 388
Palermo 379
Dublin 347
Des Moines 273
Princeton 255
Altamura 251
Nanjing 232
Lawrence 184
San Diego 172
Dearborn 145
Beijing 133
Boardman 127
Tulsa 118
New York 98
Ludwigshafen am Rhein 88
Shenyang 77
Milan 75
Brussels 67
Nanchang 64
Hebei 60
London 56
Seongnam 56
Rome 54
Tianjin 53
Changsha 47
Jinan 45
Izmir 41
Jiaxing 41
San Paolo di Civitate 40
Zhengzhou 40
Bremen 38
Falls Church 34
Redwood City 34
Helsinki 33
Verona 32
Kumar 30
Ningbo 30
Phoenix 27
Washington 26
Los Angeles 25
Saint Petersburg 25
Tehran 25
Venice 24
Duncan 22
Guangzhou 21
Taizhou 21
Montréal 20
Auburn Hills 19
Orange 19
Hangzhou 17
San Mateo 17
Napoli 16
Regensburg 16
San Jose 16
Kilburn 15
Norwalk 14
Ottawa 14
Chicago 13
Kunming 13
Catania 12
Haikou 12
Toronto 12
Pune 11
Biandronno 10
Lanzhou 10
Moscow 10
Shanghai 10
Central 9
Kraków 9
Redmond 9
Torino 9
Turin 9
Hounslow 8
Marigliano 8
Sciara 8
Treviso 8
West Jordan 8
Agrigento 7
Central District 7
Chiswick 7
Den Haag 7
Edinburgh 7
Frankfurt Am Main 7
Gualdo Tadino 7
Hefei 7
Jakarta 7
Taiyuan 7
Walnut 7
Bologna 6
Brno 6
Totale 16.261
Salva come PNG Salva come JPEG
Nome #
Curva da carico orale di metionina nella valutazione di pazienti affetti da patologia trombotica 528
Absolute Lymphocyte Count Is Unrelated to Overall Survival in Newly Diagnosed Elderly Patients with Multiple Myeloma Treated with Immunomodulatory Drugs. 341
Clinical phenotype and response to different lines of therapy in elderly with immune thrombocytopenia: A retrospective study 254
null 231
Peripheral circulating cells with paroxysmal nocturnal haemoglobinuria phenotype after a first episode of cerebral sinus vein thrombosis: Results from a multicentre cross-sectional study 196
Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system 192
Cardiovascular risk in polycythemia vera: Thrombotic risk and survival: Can cytoreductive therapy be useful in patients with low-risk polycythemia vera with cardiovascular risk factors? 180
EGFR genomic alterations in cancer: prognostic and predictive values 174
Comparison between thrombotic risk scores in Essential Thrombocythemia and survival implications 171
Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: the extended DACUS study. 170
Successful Treatment of Gastrointestinal Bleeding With Recombinant Factor VIIa After Kidney Transplantation in Patients With Pancytopenia. 164
Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate 164
Home therapy for deep vein thrombosis and pulmonary embolism in cancer patients 164
Bleeding Prophylaxis in a Child With Cleft Palate and Factor VII Deficiency: A Case Report 162
Incidence of thromboembolic complications in patients with atrial fibrillation or mechanical heart valves with a subtherapeutic international normalized ratio: a prospective multicenter cohort study 153
Low molecular weight heparins in cancer patients: to treat thromboembolic events, the tumor, of both? 150
Acquired haemophilia in cancer: A systematic and critical literature review 150
Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: Critical review of the literature 149
Gastrointestinal bleeding due to angiodysplasia in patients with type 1 von Willebrand disease: report on association and management 148
Iron-dependent erythropoiesis in women with excessive menstrual blood losses and women with normal menses 147
The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study 145
Hemorheological parameters in Monoclonal Gammopathy of Undetermined Significance (MGUS) 142
Activated prothrombin complex concentrate (FEIBA®) in acquired haemophilia A: a large multicentre Italian study - the FAIR Registry 142
Immunosenescence and lymphomagenesis 142
Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: The Duration of Anticoagulation based on Compression Ultrasonography (DACUS) study 139
Factor VII Deficiency: Clinical Phenotype, Genotype and Therapy 138
The risk of recurrent cardiovascular events in patients with increased plasma homocysteine levels is reduced by short but not long-term therapy with folate and B vitamins. 135
Optimal Duration of Low Molecular Weight Heparin for the Treatment of Cancer-Related Deep Vein Thrombosis: The Cancer-DACUS Study. 134
Cancer patients requiring interruption of long-term warfarin because of surgery or chemotherapy induced thrombocytopenia: the use of fixed sub-therapeutic doses of low-molecular weight heparin. 133
Health-related quality of life and psychological well-being in elderly patients with haemophilia 133
Patients requiring interruption of long-term oral anticoagulant therapy: the use of fixed sub-therapeutic doses of low-molecular-weight heparin 131
Buffy coat-derived platelets cryopreserved using a new method: Results from a pivotal clinical trial on thrombocytopenic patients with acute leukaemia 130
Italian Registry of Haemophilia and Allied Disorders. Objectives, methodology and data analysis 129
Splenomegaly impacts prognosis in essential thrombocythemia and polycythemia vera: A single center study 129
Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogues 128
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma 127
Buffy coat-derived platelets cryopreserved using a new method: Results from in vitro studies 127
Tailoring haemophilia A prophylaxis with BAY 81-8973: A case series 126
Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab. 125
Extracellular vesicle microRNAs contribute to the osteogenic inhibition of mesenchymal stem cells in multiple myeloma 125
Quality of Life in Patients With Cancer Under Prolonged Anticoagulation for High-Risk Deep Vein Thrombosis: a Long-Term Follow-Up 125
Hematopoietic peripheral circulating blood stem cells as an independent marker of good transfusion management in patients with β-thalassemia: results from a preliminary study 124
Cardio-oncology in multiple myeloma: is it time for a specific focus? 124
Role of clinical and laboratory parameters for treatment choice in patients with inherited FVII deficiency undergoing surgical procedures: evidence from the STER registry 124
Long term outcomes of patients with cerebral vein thrombosis: a multicenter study. 123
Recurrent venous thromboembolism complicated by heparin-induced thrombocytopenia as a first manifestation of an occult cancer: a case report. 122
Erythrocyte deformability and hemorheological profile in multiple myeloma 122
Aspirin for preventing the recurrence of venous thromboembolism 121
Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease 121
Clinical implications of discordant early molecular responses in CML patients treated with imatinib 119
CARDIOVASCULAR RISK IN ESSENTIAL THROMBOCYTHEMIA AND POLYCYTHEMIA VERA: THROMBOTIC RISK AND SURVIVAL 119
Combined Point of Care Tools Are Able to Improve Treatment Adherence and Health-Related Quality of Life in Patients with Severe Hemophilia: An Observational Prospective Study 118
Abdominal aortic thrombosis secondary to reactive thrombocytosis in a patient with iron deficiency anemia 117
Superficial venous thrombosis: Prevalence of common genetic risk factors and their role on spreading to deep veins 115
Residual vein thrombosis and D-dimer for optimizing duration of anticoagulation in idiopathic deep vein thrombosis. 115
Hematopoietic Peripheral Circulating Blood Stem Cells As an Independent Marker of Good Transfusion Management in Patients with Beta-Thalassemia 114
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 114
Red blood cell deformability in multiple myeloma 112
Trisomy 11: prevalence among 22 403 unique patient cytogenetic studies and clinical correlates. 111
Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. 111
Peri-operative bridgning therapy with low molecular weight heparin in patients requiring interruption of long-term oral anticoagulant therapy 110
Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: Data from the FAIR registry 109
Future directions in acquired hemophilia A 109
Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly. 108
Status of Recombinant Factor VIII Concentrate Treatment for Hemophilia a in Italy: Characteristics and Clinical Benefits 108
Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acquired haemophilia A: data from FAIR Registry 107
Deferral of assessment of pulmonary embolism 106
The Persistance of Residual Vein Thrombosis, after an Episode of Deep Vein Thrombosis, and the Risk of New Overt Cancer and Cardiovascular Disease 106
Emotions and Opinions of Adult Patients with Haemophilia During the COVID-19 (Coronavirus Disease 2019) Pandemic Caused by SARS-CoV-2: A Monocentric Survey 106
Lymphomas and thyroid: Bridging the gap 105
Acquired Hemophilia A Associated with Venous Thrombosis and Very High Inhibitor Titer: A Challenging Scenario 105
Antimicrobial prophylaxis in patients with immune thrombocytopenia treated with rituximab: a retrospective multicenter analysis 105
Low molecular weight heparins as antineoplastic agents. 104
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 104
Clinical experience with retrievable vena cava filters: results of a prospective observational multicenter study. 103
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation -a look beyond the excellent results 103
The MASTER registry on venous thromboembolism: description of the study cohort. 102
Management of Venous ThromboEmbolism in patients with acute leukemia at high bleeding risk: a multicenter study 102
Prevalence of renal failure and use of antithrombotic prophylaxis among medical inpatients at increased risk of venous thromboembolic events. 101
Cardiovascular events and intensity of treatment in polycythemia vera. 101
Coronary artery stenosis treatment in aging patients with inherited Factor VII deficiency: Where do we stand? 101
Evaluation of Bone Marrow CD8+ tissue-Resident Memory T Cells in Multiple Myeloma 101
Managing bleeding complications in patients treated with the old and the new anticoagulants. 100
Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature 100
Deep vein thrombosis and pulmonary embolism can be treated at home in cancer patients 99
Thigh-length versus below-knee compression elastic stockings for prevention of the postthrombotic syndrome in patients with proximal-venous thrombosis: a randomized trial. 99
Persistance of residual vein thrombosis after an episode of deep vein thrombosis of the lower limbs and the risk of new cancer and cardiovascular disease. 98
PERIOPERATIVE BRIDGING THERAPY WITH LOW MOLECULAR WEIGH HEPARIN IN PATIENTS REQUIRING INTERRUPTION OF LONG-TERM ORAL ANTICOAGULANT THERAPY 98
Incidence of venous thromboembolism in patients undergoing thoracotomy for lung cancer. 97
Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. 97
Recombinant, activated factor VII for surgery in factor VII deficiency: a prospective evaluation - the surgical STER 97
Optimizing Tumor-Reactive γδ T Cells for Antibody-Based Cancer Immunotherapy 96
Survival in young patients with intermediate/high-risk myelofibrosis: estimates derived from databases for non transplant patients. 96
Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial 96
Factors associated with the timing of diagnosis of venous thromboembolism: results from the MASTER registry 96
Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review 96
MESENCHYMAL STEM CELLS IN PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS: IDLE OBSERVERS OR PART OF THE DISEASE? 96
Residual vein thrombosis assessment estabilishes the optimal duration of oral anticoagulants in patients with idiopatic or provoked deep vein thrombosis 95
Management of bleeding and of invasive procedures in patients with platelet disorders and/or thrombocytopenia: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). 95
Trombosi portale mesenterica idiopatica in paziente con doppia mutazione eterozigote del gene C677T e del gene A1298C della MTHFR 94
Totale 13.070
Salva come PNG Salva come JPEG
Categoria #
all - tutte 84.230
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 84.230
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019888 0 0 0 0 0 0 0 0 0 0 454 434
2019/20205.443 583 182 318 501 569 790 608 344 634 305 388 221
2020/20214.349 160 416 537 601 379 213 314 282 393 332 347 375
2021/20223.008 195 591 79 130 84 160 148 155 350 396 204 516
2022/20233.912 392 733 96 405 411 619 225 307 449 45 157 73
2023/20241.721 91 286 167 280 153 356 215 88 26 58 1 0
Totale 23.412